September 25, 2015
Apotex v. Sanofi-Aventis
The parties entered into a written settlement agreement related to patent infringement litigation over a generic to the brand-name medication Plavix, a blood thinner.Ā Certain aspects of the settlement were subject to regulatory approval. Apotex alleged that the defendants made false statements to various regulators which prevented the approval of the contract and delayed the entry of Apotexās generic Plavix.
Econ One was retained by counsel for Apotex in the case Apotex v. Sanofi-Aventis. Econ One expert Jeffrey Leitzinger calculated Apotexās lost profits as a result of its delayed entry into the market. Dr. Leitzinger provided testimony both at deposition and at trial regarding Apotexās lost profits.